Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinoma 2Spinal Cord Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrent Squamous Cell Lung Carcinoma 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Urothelial Carcinoma 1Lymphoid Interstitial Pneumonia 1Fallopian Tube Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 3vocimagene amiretrorepvec 2Radiotherapy 2Lomustine 2Bevacizumab 2Vorinostat 1Vincristine 1Radiation 1Procarbazine 1Immunoglobulin G 1Flucytosine 1Disulfides 1DNA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Astrocytoma × Disulfides × Clear all
NCT01236560 2024-02-20

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

National Cancer Institute (NCI)

Phase 2/3 Completed
101 enrolled 15 charts
CNS

Astrocytoma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡